Come work with us.

Eligo Bioscience develops a new class of biotherapeutics called Eligobiotics® that enable precision-editing of the microbiome using phage-derived particles to deliver synthetic DNA payloads into bacteria for applications including sequence-specific antimicrobials, gene editing, and function addition to the microbiome.